Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9BTE6

UPID:
AASD1_HUMAN

ALTERNATIVE NAMES:
Alanyl-tRNA synthetase domain-containing protein 1

ALTERNATIVE UPACC:
Q9BTE6; B4DI73

BACKGROUND:
The Alanyl-tRNA editing protein Aarsd1, alternatively known as Alanyl-tRNA synthetase domain-containing protein 1, is integral to the fidelity of protein synthesis. By editing the amino acid moiety from incorrectly charged tRNA(Ala), it plays a pivotal role in ensuring the accuracy of the genetic code translation into functional proteins.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionality of Alanyl-tRNA editing protein Aarsd1 offers a promising avenue for drug discovery. Given its critical role in the correction of tRNA mischarging, targeting this protein could lead to innovative treatments for conditions associated with errors in protein synthesis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.